# On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)

> **NCT01670162** · PHASE4 · UNKNOWN · sponsor: **Tennessee Retina** · enrollment: 30 (actual)

## Conditions studied

- Age Related Macular Degeneration
- Pigment Epithelial Detachment

## Interventions

- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT01670162
- **Lead sponsor:** Tennessee Retina
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-08
- **Primary completion:** 2015-11
- **Final completion:** 2016-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2014-10-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01670162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01670162, "On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT01670162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*